Hospital and Internal Medicine Podcast
11min2022 JAN 28
エピソードを再生する
いいね
コメント
シェアする

詳細

Thedouble-blind, randomized phase III EMPEROR-Preservedtrial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). Now let us dig a bit more into those headlines.

see more